Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $29.4600 (-0.34%) ($29.2840 - $30.5400) on Wed. Nov. 25, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.27% (three month average) | RSI | 53 | Latest Price | $29.4600(-0.34%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.6% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.635% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) EDOC(-3%) TBT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.635% (StdDev 3.27%) | Hourly BBV | -1.2 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $29.76(-1.01%) | 10 Day Moving Average | $29.51(-0.17%) | 20 Day Moving Average | $28.54(3.22%) | To recent high | -5.4% | To recent low | 24.2% | Market Cap | $3.731b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |